Targeted Therapy Comes to AML: Now What?

CE / CME

Targeted Therapy Comes to AML: Now What?

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credit

Nurse Practitioners: 1.50 Nursing contact hours, includes 1.50 hour of pharmacotherapy credit

Released: September 28, 2022

Expiration: September 27, 2023

Melissa Dove
Melissa Dove, MSBS, PA-C
Natasha L. Johnson
Natasha L. Johnson, MSN, APRN, AOCNP

Pretest

Progress
1 2
Course Completed
1.
For a patient receiving enasidenib, a combination of unexplained hypotension and which of the following additional symptoms would be diagnostic of IDH differentiation syndrome?
2.
Which of the following targeted therapies is approved for patients with newly diagnosed acute myeloid leukemia (AML) and an FTL3 mutation?
3.
For patients with relapsed/refractory AML, molecular testing should include testing for which of the following mutations?
4.
How often do you currently consider approved targeted therapies such as FLT3 and IDH inhibitors for your patients with relapsed/refractory AML?
5.
How often do you currently discuss tumor lysis syndrome with your patients who are taking venetoclax + azacitidine for newly diagnosed AML?
6.
How often do you currently verify that molecular testing has been ordered before making treatment decisions for your patients with AML?